Saliva-based methods for SARS-CoV-2 testing in low- and middle-income countries

Simple item page
dc.contributor.authorTan, Steph H.
dc.contributor.authorAllicock, Orchid M.
dc.contributor.authorKatamba, Achilles
dc.contributor.authorCarrington, Christine V. F.
dc.contributor.authorWyllie, Anne L.
dc.contributor.authorArmstrong- Hough, Mari
dc.date.accessioned2023-01-19T17:44:22Z
dc.date.available2023-01-19T17:44:22Z
dc.date.issued2022
dc.description.abstractAs the coronavirus disease 2019 (COVID-19) continues to disproportionately affect low- and middle-income countries, the need for simple, accessible and frequent diagnostic testing grows. In lower-resource settings, case detection is often limited by a lack of available testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To address global inequities in testing, alternative sample types could be used to increase access to testing by reducing the associated costs. Saliva is a sensitive, minimally invasive and inexpensive diagnostic sample for SARS-CoV-2 detection that is appropriate for asymptomatic surveillance, symptomatic testing and at-home collection. Saliva testing can lessen two major challenges faced by lower- and middle-income countries: constrained resources and overburdened health workers. Saliva sampling enables convenient self-collection and requires fewer resources than swab-based methods. However, saliva testing for SARS-CoV-2 diagnostics has not been implemented on a large scale in low- and middle-income countries. While numerous studies based in these settings have demonstrated the usefulness of saliva sampling, there has been insufficient attention on optimizing its implementation in practice. We argue that implementation science research is needed to bridge this gap between evidence and practice. Low- and middle income countries face many barriers as they continue their efforts to provide mass COVID-19 testing in the face of substantial inequities in global access to vaccines. Laboratories should look to replicate successful approaches for sensitive detection of SARS-CoV-2 in saliva, while governments should act to facilitate mass testing by lifting restrictions that limit implementation of saliva-based methods.en_US
dc.identifier.citationTan, S. H., Allicock, O. M., Katamba, A., Carrington, C. V., Wyllie, A. L., & Armstrong-Hough, M. (2022). Saliva-based methods for SARS-CoV-2 testing in low-and middle-income countries. Bulletin of the World Health Organization, 100(12), 808-814. http://dx.doi.org/10.2471/BLT.22.288526en_US
dc.identifier.urihttp://dx.doi.org/10.2471/BLT.22.288526
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/7073
dc.language.isoenen_US
dc.publisherBulletin of the World Health Organizationen_US
dc.subjectSaliva-based methodsen_US
dc.subjectSARS-CoV-2 testingen_US
dc.subjectLow- and middle-income countriesen_US
dc.titleSaliva-based methods for SARS-CoV-2 testing in low- and middle-income countriesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Saliva-based methods for SARS-CoV-2 testing in low- and.pdf
Size:
2.15 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences